Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Long-term Debt
Borrowings due after more than one year.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q1 FY2026 long-term debt was $8.19M, compared with $0 a year earlier. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Long-term debt amounted to 1.6% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 8.73M USD
- Year-over-year change
- —
- 3-year CAGR
- -5.8%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.73M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 10.44M | — |
Long-term Debt vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 long-term debt of $8.19M is the 3rd highest of the 10 companies compared; the peer median is $0.
- Long-term debt amounts to 1.6% of total assets for RAPP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $117.96M | +0.4% | +14.3% | 15.5% | |
| Sep 2026 | $57.32M | — | — | 3.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $8.19M | — | -5.8% | 1.6% |
| Mar 2026 | $3.56M | -83.2% | -64.0% | 1.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $119K | — | — | 0.1% |
| Sep 2026 | $0 | — | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $0 | — | — | 0.0% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $0 | -41.4% | -24.8% | 0.0% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.